ClinicalTrials.gg
WithdrawnNCT04717687HOPEUpdated Jul 13, 2022

Pilot Study on the Evaluation of Irreversible Electroporation Technique in Infiltrating Perihilar Cholangiocarcinoma

An interventional study of Irreversible electroporation in Cholangiocarcinoma and Interventional Imaging, sponsored by Poitiers University Hospital. Withdrawn. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-07-13.

Sponsored by Poitiers University Hospital · Not applicable, Interventional, and Treatment

Why this study was withdrawn
No enrollment
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The aim of the study is to evaluate the feasibility of irreversible electroporation in the treatment of locally advanced cholangiocarcinoma. This technique would allow to treat the unresectable part of the tumor to make it more accessible for a secondary surgery.

02

Conditions studied

  • Cholangiocarcinoma
  • Interventional Imaging

Browse trials for

Keywords

  • Cholangiocarcinoma
  • Irreversible electroporation
  • Interventional radiology
03

In context

Cholangiocarcinoma

930 studies on the registry are indexed under Cholangiocarcinoma; 292 are open to participants now.

Browse Cholangiocarcinoma studies →

Lead sponsor

Poitiers University Hospital is the lead sponsor of 314 studies on the registry; 62 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-75 years old
  • Patient with infiltrating cholangiocarcinoma of the gallstone convergence considered as unresectable on the pre-operative imaging data performed during the month preceding inclusion, and in multidisciplinary consultation meeting specialised in digestive oncology
  • Histologically (or cytologically) proven tumor of less than 4 cm of the largest diameter
  • World Health Organization Performance Index 0 or 1
  • No history of other cancer, except baso-cellular skin carcinoma or epidermoid cervix cancer or any other cancer in complete remission for more than 3 years
  • No prior radiotherapy for cholangiocarcinoma
  • Biological analyses performed during the month preceding inclusion : hepatic enzymes (AST and ALT \<3N), preserved renal function (creatinine clearance according to Modification of the Diet in Renal Disease >50ml/min); bilirubin \<3N; bile drainage must be correct with a bilirubin below 3N , with or without drainage/prothesis, hemoglobin >9g/dL, leucocytes >3500/mm3, platelets >75000/mm3, prothrombin rate >70%
  • Signature of the informed consent

Exclusion criteria

Exclusion Criteria:

  • Cholangiocarcinoma of more than 4cm diameter or resectable according tio the imaging data
  • Severe and/or uncontrolled (cardiac, pulmonary, renal, liver decompensation...) visceral failure, in the 6 months preceding the study
  • Visceral metastases or peritoneal carcinosis
  • History of cancers except if remission for more than 3 years, in-situ cancer, epidermoid or baso-cellular cancer
  • Metal biliary prothesis non extractable
  • Patient with history of epileptic events
  • History of myocard infarction for less than 6 months
  • Unstabilised coronary disease for at least 6 months
  • Cardiac rhythm trouble or QT space above 550ms without treatment
  • Patient eligible to liver transplant
  • Patient naive of chemiotherapy
  • Patient with a pacemaker, an implanted automatic defibrillator or an automatic electronic device or an electronic device with metal pieces
  • Patient with contra-indication to the use of NanoKnife system
  • History of hypersensitivity to gadolinium or to iodized contrast product not allowing a suitable radiologic monitoring
  • Refusal or language or psychic incapacity to sign the informed consent
  • Subject who cannot submit to the constraints of the protocol (subjects for which an MRI or a scan is contra-indicated, claustrophobic subjects, non cooperative or not able to come to the follow-up visits)
  • Concomitant participation to another study
  • Persons benefiting from enhanced protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, adults under legal protection.
  • Women at age to procreate and not using effective contraception
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Electrodes

    Electrodes

    Procedure: Irreversible electroporation

Interventions

  • ProcedureIrreversible electroporation

    Device: NanoKnife The aim of the treatment is to surround the tumour with two to six needles and to deliver a very high voltage current (3000 volts in 70 to 80 microseconds pulses) by a generator synchronized with an electrocardiogram.

06

What researchers measure

Primary outcomes

  1. The success rate of the technique, being the realisation of the irreversible electroporation.

    The study will be considered positive if the success rate is above 90% and the complication rate below or equal to 30%

    Time frame: At Day 0

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Jun 2022, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2021
First posted
Jan 22, 2021
StartActual
May 1, 2021
Primary completionActual
Jun 1, 2022
CompletionActual
Jun 1, 2022
Last update
Jul 13, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04717687
Collaborators
Sport & Collection 2019
Responsible party
Sponsor
First posted
Jan 22, 2021
Start date
May 1, 2021
Primary completion
Jun 1, 2022
Completion
Jun 1, 2022
Last update
Jul 13, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion